The date of first ofatumumab prescription claim or other DMT of interest was defined as the index date. No post-index requirements were imposed.~Patients were linked to IQVIA's open source medical claims databases (Dx) to obtain patient clinical characteristics.~The initial data were extracted in October 2020. The data and results were refreshed in April 2021 and July 2021 to allow for assessment of changes in characteristics at 6 and 9 months post-launch.
This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.